China's Sinopharm starts Phase III trial of Covid-19 vaccine in Bahrain
The human trial, which launched in the UAE capital Abu Dhabi in mid-July, is a partnership between Sinopharm’s China National Biotec Group (CNBG) and Abu Dhabi-based artificial intelligence and cloud computing company Group 42 (G42)
Chinese state-owned pharmaceutical company Sinopharm has begun Phase III clinical trials of a Covid-19 vaccine in Bahrain, after launching similar trials in the United Arab Emirates last month, Bahrain's health ministry said on Monday.
The human trial, which launched in the UAE capital Abu Dhabi in mid-July, is a partnership between Sinopharm's China National Biotec Group (CNBG) and Abu Dhabi-based artificial intelligence and cloud computing company Group 42 (G42).
G42 Healthcare CEO Ashish Koshy said expanding the trial to the small island state of Bahrain will increase the numbers of participants on a par with trials underway in nations with much larger populations.
The study, which uses an inactivated vaccine, will include around 6,000 citizens and resident volunteers in Bahrain over 12 months, the health ministry said.
No Covid-19 vaccine has yet been approved for commercial use.
The trial in the UAE, which was expanded from Abu Dhabi to include another centre in Sharjah emirate, on Thursday reached a milestone of 5,000 vaccinations, a joint statement from the trial organisers said.
Bahrain, with a population of 1.5 million, has recorded more than 44,000 cases of the new coronavirus and 162 deaths.
